Big Money Sentiment decreased to 0.86 in 2018 Q3. It has change of 0.15, from 2018Q2’s 1.01. The ratio worsened due to Bio-Techne Corporation positioning: 30 sold and 112 reduced. 52 funds amassed positions and 70 increased positions. Investors holded 37.29 million in 2018Q2 but now own 34.66 million shares or 7.06% less.
Nordea Mngmt Ab has invested 0.01% in Bio-Techne Corporation (NASDAQ:TECH). Ameriprise Financial Inc accumulated 0.05% or 650,749 shs. First Bancorporation Of Omaha, Nebraska-based fund reported 27,360 shs. Robeco Institutional Asset Mgmt Bv accumulated 108 shs. Ajo Lp holds 0.03% of its capital in Bio-Techne Corporation (NASDAQ:TECH) for 28,634 shs. California Employees Retirement Sys invested in 0.02% or 76,158 shs. Captrust Fin Advisors has invested 0.1% in Bio-Techne Corporation (NASDAQ:TECH). The Minnesota-based Palisade Asset Ltd has invested 0.41% in Bio-Techne Corporation (NASDAQ:TECH). Brown Advisory accumulated 9,332 shs. Parkside Bank & Trust Trust invested in 0.04% or 563 shs. Whittier Tru Of Nevada owns 0% invested in Bio-Techne Corporation (NASDAQ:TECH) for 250 shs. Sun Life Financial reported 3,004 shs stake. The United Kingdom-based Mondrian Invest Prtnrs has invested 0.17% in Bio-Techne Corporation (NASDAQ:TECH). Friess Associates Limited has 141,786 shs. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 2,371 shs.
Bio-Techne Corporation (NASDAQ:TECH) Ratings Coverage
A total of 4 analysts rate Bio-Techne (NASDAQ:TECH) as follows: 2 “Buy”, 2 “Hold” and 0 “Sell”. Š¢herefore 50% are bullish. (NASDAQ:TECH) has 4 ratings reports on Feb 24, 2019 according to StockzIntelligence. On Wednesday, October 31 the firm has “Hold” rating given by Craig Hallum. In Monday, January 14 report Stephens upgraded the stock to “Overweight” rating. On Tuesday, October 2 Argus Research maintained Bio-Techne Corporation (NASDAQ:TECH) rating. Argus Research has “Buy” rating and $230 target. Listed here are Bio-Techne Corporation (NASDAQ:TECH) PTs and latest ratings.
14/01/2019 Broker: Stephens Old Rating: Equal-Weight New Rating: Overweight New Target: $180 Upgrade
31/10/2018 Broker: Craig Hallum Old Rating: Buy New Rating: Hold Old Target: $215 New Target: $154 Downgrade
17/10/2018 Broker: Goldman Sachs Rating: Neutral New Target: $190 Initiates Coverage On
02/10/2018 Broker: Argus Research Old Rating: Buy New Rating: Buy Old Target: $210 New Target: $230 Maintain
TECH is touching $194.97 during the last trading session, after increased 0.52%.Currently Bio-Techne Corporation is uptrending after 20.74% change in last February 24, 2018. TECH has 152,329 shares volume. TECH outperformed the S&P 500 by 20.74%.
Bio-Techne Corporation, together with its subsidiaries, develops, makes, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide.The firm is valued at $7.36 billion. It operates through three divisions: Biotechnology, Protein Platforms, and Diagnostics.The P/E ratio is 78.11. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.
For more Bio-Techne Corporation (NASDAQ:TECH) news released recently go to: Cnbc.com, Nasdaq.com, Nasdaq.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Tech stocks have moved from ‘un-investable’ to good bets, and that could send the Nasdaq up 10 percent this year: Investor Paul Meeks – CNBC” released on February 09, 2019, “U.S. STOCKS ON THE MOVE-Amazon, Papa John’s, Ultimate Software, Maxwell Tech – Nasdaq” on February 04, 2019, “Indian lawmakers summon Facebook officials over citizens’ rights protection – Nasdaq” with a publish date: February 22, 2019, “Technology Sector Update for 02/21/2019: WK,PEGA,INOV – Nasdaq” and the last “Bet High on Earnings Beat by These 6 Tech Stocks – Nasdaq” with publication date: February 07, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.